Introducing us to Germitec disinfection solutions?
Germitec provides, through its automata, the reprocessing of endocavitary probes (vaginal, rectal and transesophageal) and external ultrasound, used to obtain images of areas difficult to access by external or radiological examination. The great advantages of this type of disinfection compared to conventional processes are multiple: speed, ease of use, simplification of protocols, health safety and no need to use chemicals that are harmful to the body and the environment.
Even today, probes are sometimes disinfected in buckets of detergent products or simply cleaned with disinfectant wipes. Germitec offers a high level of ultra-fast disinfection in 90 seconds associated with digital traceability. This chemical-free system is changing clinical practice, allowing high-level UV-C disinfection to become the standard in all hospitals and clinical departments.
Why is the fight against infectious risks an important issue for healthcare establishments?
Since the health crisis, we are talking more and more about nosocomial diseases, which are contracted in the hospital setting (1 in 20 hospitalized patients in France). These are often viruses or bacteria. Most are treated with immune defenses or antibiotics, but some infections are more discreet. The papilloma virus, which can be contracted during gynecological exams, or golden staphylococcus, which can be very dangerous and difficult to treat.
Germitec’s main objective is to develop hospital hygiene systems that radically simplify the life of healthcare professionals in terms of safety, time and responsibility. In short, our products allow medical personnel to change clinical practice habits and considerably reduce the risk of cross-infections and thus improve the quality of care provided to patients.
It is a major public health problem and represents a huge cost to the health system.
How are the markets in which you operate?
The medical technology market in France represents 30 billion per year and has an organic growth of 5% per year. The ultrasound market has been booming for two decades thanks to advances in imaging technology.
What are your development ambitions?
Founded in 2005, Germitec is a French family business based in Bordeaux. In 2021, Germitec brought in new investors, who subsequently became shareholders. The ambition is to transform this tech start-up into an excellent, high-growth business venture. The company had a dozen employees at the beginning of the adventure, and in 2022, 40 people have joined the structure.
We market our products for endocavitary ultrasound probes in more than 35 countries, but UV-C can be used for other medical applications, such as ENT or Emergencies.
Geographically, the market with the most potential for Germitec is the United States, where we hope to launch our product in 2023, and in general all the Anglo-Saxon countries, which were the first to establish standards that strictly regulate the disinfection of these endocavitaries. probes
This content was produced with SCRIBEO. The BFMBUSINESS editorial team was not involved in the production of this content.
Source: BFM TV
